Aflatoxin B1 transfer and metabolism in human placenta

Toxicological Sciences

Volumn 113, Issue 1, 2009, Pages 216-225

  Partanen, Heidi A ^a   El Nezami, Hani S ^b   Leppänen, Jukka M ^a   Myllynen, Päivi K ^c   Woodhouse, Heather J ^a   Vähäkangas, Kirsi H ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

Aflatoxicol; Dietary carcinogen; Fetal exposure; Human placental perfusion; Placental cytosolic fraction

Indexed keywords

AFLATOXICOL; AFLATOXIN B1; CHORIONIC GONADOTROPIN;

ARTICLE; BLOOD PLACENTA BARRIER; CARCINOGEN DNA INTERACTION; CARCINOGENICITY; CONTROLLED STUDY; CYTOSOL; FETOTOXICITY; FETUS CIRCULATION; GLUCOSE INTAKE; HUMAN; HUMAN TISSUE; MATERNAL BLOOD; METABOLISM; MUTAGENICITY; PASSIVE TRANSPORT; PLACENTA PERFUSION; PLACENTAL TRANSFER;

AFLATOXIN B1; AFLATOXINS; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOSOL; DNA; FEMALE; HUMANS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MATERNAL-FETAL EXCHANGE; MICROSOMES; MUTAGENS; PLACENTA; PREGNANCY;

EID: 75249093115     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfp257     Document Type: Article

References (51)

1. Abdulrazzaq, Y.M., Osman, N., and Ibrahim, A. (2002). Fetal exposure to aflatoxins in the United Arab Emirates. Ann. Trop. Paediatr. 22, 3.
2. Bailey, G.S., Dashwood, R., Loveland, P.M., Pereira, C., and Hendricks, J.D. (1998). Molecular dosimetry in fish: quantitative target organ DNA adduction and hepatocarcinogenicity for four aflatoxins by two exposure routes in rainbow trout. Mutat. Res. 399, 233-244.
3. Bailey, G.S., Loveland, P.M., Pereira, C., Pierce, D., Hendricks, J.D., and Groopman, J.D. (1994). Quantitative carcinogenesis and dosimetry in rainbow trout for aflatoxin B1 and aflatoxicol, two aflatoxins that form the same DNA adduct. Mutat. Res. 313, 25-38.
4. Bassily, M., Ghabrial, H., Smallwood, R.A., and Morgan, D.J. (1995). Determinants of placental drug transfer: studies in the isolated perfused human placenta. J. Pharm. Sci. 84, 1054-1060.
5. Behravan, J., and Piquette-Miller, M. (2007). Drug transport across the placenta, role of the ABC drug efflux transporters. Expert Opin. Drug Metab. Toxicol. 3, 819-830.
6. Brandes, J.M., Tavoloni, N., Potter, B.J., Sarkozi, L., Shepard, M.D., and Berk, P.D. (1983). A new recycling technique for human placental cotyledon perfusion: application to studies of the fetomaternal transfer of glucose, inulin, and antipyrine. Am. J. Obstet. Gynecol. 146, 800-806.
7. Bunin, G.R. (2004). Nongenetic causes of childhood cancers: evidence from international variation, time trends, and risk factor studies. Toxicol. Appl. Pharmacol. 199, 91-103.
8. Datta, K., and Kulkarni, A.P. (1994). Oxidative metabolism of aflatoxin B1 by lipoxygenase purified from human term placenta and intrauterine conceptal tissues. Teratology 50, 311-317.
9. De Vries, H.R., Maxwell, S.M., and Hendrickse, R.G. (1989). Foetal and neonatal exposure to aflatoxins. Acta Paediatr. Scand. 78, 373-378.
10. Denning, D.W., Allen, R., Wilkinson, A.P., and Morgan, M.R. (1990). Transplacental transfer of aflatoxin in humans. Carcinogenesis 11, 1033-1035.
11. Di Santo, S., Malek, A., Sager, R., Andres, A.C., and Schneider, H. (2003). Trophoblast viability in perfused term placental tissue and explant cultures limited to 7-24 hours. Placenta 24, 882-894.
12. Doi, A.M., Patterson, P.E., and Gallagher, E.P. (2002). Variability in aflatoxin B(1)-macromolecular binding and relationship to biotransformation enzyme expression in human prenatal and adult liver. Toxicol. Appl. Pharmacol. 181, 48-59.
13. Dreifaldt, A.C., Carlberg, M., and Hardell, L. (2004). Increasing incidence rates of childhood malignant diseases in Sweden during the period 1960-1998. Eur. J. Cancer 40, 1351-1360.
14. Eaton, D.L., and Gallagher, E.P. (1994). Mechanisms of aflatoxin carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 34, 135-172.
15. Gallagher, E.P., Wienkers, L.C., Stapleton, P.L., Kunze, K.L., and Eaton, D.L. (1994). Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Res. 54, 101-108.
16. Gluckman, P.D., Hanson, M.A., Cooper, C., and Thornburg, K.L. (2008). Effect of in utero and early-life conditions on adult health and disease. N. Engl. J. Med. 359, 61-73.
17. Godschalk, R.W., and Kleinjans, J.C. (2008). Characterization of the exposure-disease continuum in neonates of mothers exposed to carcinogens during pregnancy. Basic Clin. Pharmacol. Toxicol. 102, 109-117.
18. Gong, Y., Hounsa, A., Egal, S., Turner, P.C., Sutcliffe, A.E., Hall, A.J., Cardwell, K., and Wild, C.P. (2004). Postweaning exposure to aflatoxin results in impaired child growth: a longitudinal study in Benin, West Africa. Environ. Health Perspect. 112, 1334-1338.
19. Guengerich, F.P., Johnson, W.W., Shimada, T., Ueng, Y.F., Yamazaki, H., and Langouet, S. (1998). Activation and detoxication of aflatoxin B1. Mutat. Res. 402, 121-128.
20. Hakkola, J., Pasanen, M., Hukkanen, J., Pelkonen, O., Maenpaa, J., Edwards, R.J., Boobis, A.R., and Raunio, H. (1996a). Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem. Pharmacol. 51, 403-411.
21. Hakkola, J., Raunio, H., Purkunen, R., Pelkonen, O., Saarikoski, S., Cresteil, T., and Pasanen, M. (1996b). Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem. Pharmacol. 52, 379-383.
22. Hsieh, L.L., and Hsieh, T.T. (1993). Detection of aflatoxin B1-DNA adducts in human placenta and cord blood. Cancer Res. 53, 1278-1280.
23. IARC. (2003). Cancer in Africa: epidemiology and prevention. IARC Sci. Publ. 153, 381-396.
24. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. (2002). Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr. Eval. Carcinog. Risks Hum. 82, 1-556.
25. Kitada, M., and Kamataki, T. (1994). Cytochrome P450 in human fetal liver: significance and fetal-specific expression. Drug Metab. Rev. 26, 305-323.
26. Loe, D.W., Stewart, R.K., Massey, T.E., Deeley, R.G., and Cole, S.P. (1997). ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol. Pharmacol. 51, 1034-1041.
27. McCann, J., Choi, E., Yamasaki, E., and Ames, B.N. (1975). Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. Proc. Natl. Acad. Sci. U.S.A. 72, 5135-5139.
28. Myllynen, P., Kummu, M., Kangas, T., Ilves, M., Immonen, E., Rysa, J., Pirila, R., Lastumaki, A., and Vahakangas, K.H. (2008). ABCG2/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in perfused term human placenta. Toxicol. Appl. Pharmacol. 232, 210-217.
29. Myllynen, P., Pasanen, M., and Vahakangas, K. (2007). The fate and effects of xenobiotics in human placenta. Expert Opin. Drug Metab. Toxicol. 3, 331-346.
30. Myllynen, P.K., Pienimaki, P.K., and Vahakangas, K.H. (2003). Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo. Eur. J. Clin. Pharmacol. 58, 677-682.
31. Neri, M., Ugolini, D., Bonassi, S., Fucic, A., Holland, N., Knudsen, L.E., Sram, R.J., Ceppi, M., Bocchini, V., and Merlo, D.F. (2006). Children's exposure to environmental pollutants and biomarkers of genetic damage. II. Results of a comprehensive literature search and meta-analysis. Mutat. Res. 612, 14-39.
32. Pallapies, D. (2006). Trends in childhood disease. Mutat. Res. 608, 100-111.
33. Pasanen, M. (1999). The expression and regulation of drug metabolism in human placenta. Adv. Drug Deliv. Rev. 38, 81-97.
34. Pavek, P., and Dvorak, Z. (2008). Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr. Drug Metab. 9, 129-143.
35. Perera, F., Hemminki, K., Jedrychowski, W., Whyatt, R., Campbell, U., Hsu, Y., Santella, R., Albertini, R., and O'Neill, J.P. (2002). In utero DNA damage from environmental pollution is associated with somatic gene mutation in newborns. Cancer Epidemiol. Biomarkers Prev. 11, 1134-1137.
36. Pienimaki, P., Hartikainen, A.L., Arvela, P., Partanen, T., Herva, R., Pelkonen, O., and Vahakangas, K. (1995). Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood. Epilepsia 36, 241-248.
37. Polychronaki, N., Wild, C.P., Mykkanen, H., Amra, H., Abdel-Wahhab, M., Sylla, A., Diallo, M., El-Nezami, H., and Turner, P.C. (2008). Urinary biomarkers of aflatoxin exposure in young children from Egypt and Guinea. Food Chem. Toxicol. 46, 519-526.
38. Salhab, A.S., and Edwards, G.S. (1977). Comparative in vitro metabolism of aflatoxicol by liver preparations from animals and humans. Cancer Res. 37, 1016-1021.
39. Sawada, M., Kitamura, R., Norose, T., Kitada, M., Itahashi, K., and Kamataki, T. (1993). Metabolic activation of aflatoxin B1 by human placental microsomes. J. Toxicol. Sci. 18, 129-132.
40. Schneider, H., Panigel, M., and Dancis, J. (1972). Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am. J. Obstet. Gynecol. 114, 822-828.
41. Tachampa, K., Takeda, M., Khamdang, S., Noshiro-Kofuji, R., Tsuda, M., Jariyawat, S., Fukutomi, T., Sophasan, S., Anzai, N., and Endou, H. (2008). Interactions of organic anion transporters and organic cation transporters with mycotoxins. J. Pharmacol. Sci. 106, 435-443.
42. Turner, P.C., Collinson, A.C., Cheung, Y.B., Gong, Y., Hall, A.J., Prentice, A.M., and Wild, C.P. (2007). Aflatoxin exposure in utero causes growth faltering in Gambian infants. Int. J. Epidemiol. 36, 1119-1125.
43. Turner, P.C., Moore, S.E., Hall, A.J., Prentice, A.M., and Wild, C.P. (2003). Modification of immune function through exposure to dietary aflatoxin in Gambian children. Environ. Health Perspect. 111, 217-220.
44. Vahakangas, K., Haugen, A., and Harris, C.C. (1985). An applied synchronous fluorescence spectrophotometric assay to study benzo[a]pyrene-diolepoxide-DNA adducts. Carcinogenesis 6, 1109-1115.
45. Vahakangas, K., Raunio, H., Pasanen, M., Sivonen, P., Park, S.S., Gelboin, H.V., and Pelkonen, O. (1989). Comparison of the formation of benzo[a]pyrene diolepoxide-DNA adducts in vitro by rat and human microsomes: evidence for the involvement of P-450IA1 and P-450IA2. J. Biochem. Toxicol. 4, 79-86.
46. van Herwaarden, A.E., Wagenaar, E., Karnekamp, B., Merino, G., Jonker, J.W., and Schinkel, A.H. (2006). Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 27, 123-130.
47. Wang, J.S., Newport, D.J., Stowe, Z.N., Donovan, J.L., Pennell, P.B., and DeVane, C.L. (2007). The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. Drug Metab. Rev. 39, 723-746.
48. Wild, C.P., and Kleinjans, J. (2003). Children and increased susceptibility to environmental carcinogens: evidence or empathy? Cancer Epidemiol. Biomarkers Prev. 12, 1389-1394.
49. Wild, C.P., Rasheed, F.N., Jawla, M.F., Hall, A.J., Jansen, L.A., and Montesano, R. (1991). In-utero exposure to aflatoxin in west Africa. Lancet 337, 1602.
50. Williams, J.H., Phillips, T.D., Jolly, P.E., Stiles, J.K., Jolly, C.M., and Aggarwal, D. (2004). Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am. J. Clin. Nutr. 80, 1106-1122.
51. Wong, J.J., and Hsieh, D.P. (1976). Mutagenicity of aflatoxins related to their metabolism and carcinogenic potential. Proc. Natl. Acad. Sci. U.S.A. 73, 2241-2244.